Brief: Heartbeam Successfully Meets Clinical Endpoints In Pivotal Study For Its Groundbreaking 12-Lead ECG Synthesis Technology
29/04/2025 13:32
Heartbeam Inc BEAT.O: HEARTBEAM SUCCESSFULLY MEETS CLINICAL ENDPOINTS IN PIVOTAL STUDY FOR ITS GROUNDBREAKING 12-LEAD ECG SYNTHESIS TECHNOLOGY Source text: ID:nBw9HSrRHa Further company coverage: BEAT.O
Recent news on Heartbeam
See all newsBrief: Heartbeam Announces Strategic Shift To Accelerate Global Adoption Of Its Ambulatory ECG Signal Platform And Leadership Transition
Brief: Heartbeam Reports First Quarter 2026 Results
HeartBeam Q1 net loss narrows as commercialization advances
Brief: Heartbeam Initiates Pilot Study Of First On-Demand 12-Lead ECG Patch To Detect Ischemia Outside The Clinic
Brief: Heartbeam Expands Commercial Presence Across Four Key U.S. Markets With Addition Of Premier Concierge Practice